Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) has announced that its subsidiary Changzhou Pharmaceutical Factory Co., Ltd. recently received notification from the U.S. Food and Drug Administration (FDA) that its Abbreviated New Drug Application (ANDA) for Eltrombopag Tablets has been approved for marketing.
The drug is primarily used for chronic immune (idiopathic) thrombocytopenia and severe aplastic anemia. It was originally developed by Novartis and launched in the United States in 2008.
According to the IMS database, sales of this drug in the United States were approximately USD 217 million in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments